U.S. markets open in 5 hours 37 minutes

Fluidigm Corporation (FLDM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
7.43+0.01 (+0.13%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Fast Stochastic

Fast Stochastic

Previous Close7.42
Open7.35
Bid0.00 x 800
Ask0.00 x 1800
Day's Range7.01 - 7.68
52 Week Range1.17 - 9.26
Volume3,014,235
Avg. Volume3,112,442
Market Cap529.881M
Beta (5Y Monthly)2.34
PE Ratio (TTM)N/A
EPS (TTM)-0.78
Earnings DateNov 03, 2020 - Nov 09, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.67
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • GlobeNewswire

    Fluidigm Announces Second Quarter 2020 Financial Results

    Second Quarter Revenue Decreased 8 Percent to $26.1 Million Filed for FDA Emergency Use Authorization for COVID-19 Saliva-based TestMulti-Site U.S. Study of COVID-19 Patients Utilizes Mass Cytometry Technology and Maxpar Direct Immune Profiling Assay Fluidigm Selected for $37 Million Project under National Institutes of Health RADx InitiativeSOUTH SAN FRANCISCO, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM) today announced financial results for the second quarter ended June 30, 2020.Financial HighlightsSecond Quarter 2020 * Second quarter revenue decreased 8 percent to $26.1 million from $28.2 million in the second quarter of 2019. Product and service revenue decreased 20 percent to $22.5 million. Total revenue included $3.5 million of other revenue.   * GAAP net loss for the quarter was $13.0 million, compared with a GAAP net loss of $13.8 million for the second quarter of 2019. * Non-GAAP net loss was $5.2 million for the quarter, compared with a $7.1 million non-GAAP net loss for the second quarter of 2019.“As COVID-19 infection rates soar and test demand outpaces capacity, Fluidigm has swiftly pivoted to meet the testing and immune profiling research needs brought on by this pandemic. More significantly, we filed for Emergency Use Authorization for our extraction-free saliva test, shipped microfluidics consumables that our customers used to produce over 100,000 COVID-19 assays, and were selected for a project to expand COVID-19 testing under the National Institutes of Health Rapid Acceleration of Diagnostics initiative. At the same time, researchers are harnessing mass cytometry technology and the Maxpar Direct Immune Profiling Assay in large national government-supported COVID-19 patient studies to better understand immune response to this disease,” said Chris Linthwaite, Fluidigm President and CEO.“This quarter, we also drove actions to preserve liquidity, adding non-dilutive funding and closely managing our operating expenses,” added Linthwaite. “Moving forward, we are well-positioned to expand our efforts further in infectious disease along with our focus on biomarker discovery, disease research, and treatment paradigms linked to understanding immune function and response in a wide range of diseases.”A reconciliation of GAAP to non-GAAP financial measures can be found in the tables of this news release. Second Quarter 2020 ResultsRevenue by category: CategoryRevenue by CategoryYear-over-Year Change% of Total Revenue Instruments$8.6 million(30%)33% Consumables$8.8 million(20%)34% Service$5.1 million4%20% Other$3.5 millionN/A13% Product and service revenue by market: * Mass cytometry product and services revenue decreased 28 percent to $12.5 million from $17.5 million in the prior year period due to lower sales of instruments and consumables.   * Microfluidics product and services revenue decreased 8 percent to $10.0 million from $10.7 million in the prior year period primarily due to lower sales of consumables partially offset by higher sales of instruments.Revenue by geographic area:Geographic AreaRevenue by GeographyYear-over-Year Change% of Total Revenue Americas*$13.9 million25%54% EMEA$6.6 million(42)%25% Asia-Pacific$5.6 million(5%)21% *Americas geographic area includes Other Revenue of $3.5 millionProduct and service margin: Product and service margin was 52.5 percent in the second quarter of 2020 compared to 54.5 percent in the year ago period and 53.8 percent in the first quarter of 2020. Non-GAAP product and service margin was 67.1 percent in the second quarter of 2020 compared to 66.4 percent in the year ago period and 67.3 percent in the first quarter of 2020. The year-over-year increase in non-GAAP product and service margin was primarily due to lower service costs and improved manufacturing efficiencies across our consumables products partially offset by unfavorable product mix and higher mass cytometry instrument costs due to lower factory utilization.GAAP product and service margin, both sequentially and year-over-year, was impacted by fixed amortization over lower revenue more than offsetting lower service costs and improved manufacturing efficiencies.Cash and cash equivalents, short-term investments, and restricted cash as of June 30, 2020: Cash and cash equivalents, short-term investments, and restricted cash as of June 30, 2020, were $46.5 million. Cash and cash equivalents, short-term investments, and restricted cash as of March 31, 2020, were $49.6 million.Operational and Business Progress SARS-CoV-2 virus detection utilizing microfluidics * Fluidigm filed FDA Emergency Use Authorization (EUA) for the saliva-based Advanta™ Dx SARS-CoV-2 RT-PCR Assay for COVID-19. * Shipped microfluidics consumables that our customers used to produce over 100,000 COVID-19 assays. * Fluidigm was selected for a project of up to $37 million under the National Institutes of Health Rapid Acceleration of Diagnostics (NIH RADx) initiative. The project will expand Fluidigm production capacity and throughput capabilities for microfluidics technology in COVID-19 testing. Initial funding of up to $12 million is available based on achievement of milestones under the executed letter contract, with the remainder pending completion of definitive contract.COVID-19 immune profiling studies utilizing mass cytometry technology and Maxpar Direct Immune Profiling Assay * Through July, CyTOF® technology was included in 13 COVID-19 publications and five clinical trials. * CyTOF technology was used in an NIH sponsored clinical study of up to 2,000 adult COVID-19 patients with 10 leading U.S. medical institutions. * University of Paris researchers published findings of a unique phenotype specific to severe and critical COVID-19 patients. In-depth phenotypic analysis of immune cells was completed using the Fluidigm® Maxpar® Direct™ Immune Profiling Assay™ enabling the team at University of Paris to go from experiment conception to pre-print publication in 25 days.Product launches, collaborations and publications: * The company launched six Maxpar Direct expansion panels tailored for infectious disease and immune-oncology research. These panels can be combined with the Maxpar Direct Immune Profiling Assay.    * Launched an additional software product through a distribution agreement with De Novo Software™. The software offers mass cytometry customers a streamlined solution for high-parameter data analysis with outputs into Microsoft® Office applications, while maintaining high-resolution graphics and reports. * Announced a collaboration with Bethyl Laboratories to expand verified antibody offerings for the Hyperion™ Imaging System, based on Imaging Mass Cytometry™. * Total publications and reviews involving CyTOF technology exceeded 1,100, with more than 50 publications in Imaging Mass Cytometry. Clinical trials using CyTOF technology exceeded 100.Conference Call Information Fluidigm will host a conference call today, August 6, 2020, at 2:00 p.m. PT, 5:00 p.m. ET, to discuss second quarter 2020 financial results and operational progress. Individuals interested in listening to the conference call may do so by dialing the following:US domestic callers: (877) 556-5248 Outside US callers: (720) 545-0029 Please reference Conference ID: 2068836A live webcast of the conference call will be available online from the Investor Relations page of the company’s website at Events & Presentations. The link will not be active until 1:45 p.m. PT, 4:45 p.m. ET, on August 6, 2020.After the live webcast, the call will be archived on Fluidigm’s Investor Relations page at investors.fluidigm.com. In addition, a telephone replay of the teleconference will be available approximately 90 minutes after the end of the call.The replay dial-in numbers are:US domestic callers: (855) 859-2056 Outside US: (404) 537-3406 Please reference Conference ID: 2068836The telephone replay will be available until August 13.Statement Regarding Use of Non-GAAP Financial Information Fluidigm has presented certain financial information in accordance with U.S. GAAP and on a non-GAAP basis for the three-month periods ended June 30, 2020, and June 30, 2019. Management believes that non-GAAP financial measures, taken in conjunction with GAAP financial measures, provide useful information for both management and investors by excluding certain non-cash and other expenses that are not indicative of the company’s core operating results. Management uses non-GAAP measures to compare the company’s performance relative to forecasts and strategic plans and to benchmark the company’s performance externally against competitors. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of the company’s operating results as reported under U.S. GAAP. Fluidigm encourages investors to carefully consider its results under GAAP, as well as its supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand its business. Reconciliations between GAAP and non-GAAP operating results are presented in the accompanying tables of this release.Use of Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding opportunities for Fluidigm technology and products, including expected uses and demand for COVID-19 testing and research, potential for growth in revenues in the infectious disease markets, anticipated benefits of contractual relationships, including customers using Fluidigm technology for SARS-CoV-2 virus detection and epigenetic tests, and expectations for newly launched and recently acquired products and services. Forward‑looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to the potential adverse effects of the coronavirus pandemic on our business and operating results during 2020; the suitability and acceptance of our tools and technology by the research community pursuing solutions for the novel coronavirus pandemic; our ability and/or the ability of the institutions utilizing our products and technology to obtain FDA and any other requisite approvals to use our products and technology for diagnostic testing purposes; customers and prospective customers continuing to curtail or suspend activities utilizing our products; interruptions or delays in the supply of components or materials for, or manufacturing of, our products resulting from the pandemic or other factors; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; risks relating to reliance on sales of capital equipment for a significant proportion of revenues in each quarter; potential product performance and quality issues; the possible loss of key employees, customers, or suppliers; intellectual property risks; competition; uncertainties in contractual relationships; risks relating to company research and development, sales, marketing, and distribution plans and capabilities; reductions in research and development spending or changes in budget priorities by customers; seasonal variations in customer operations; unanticipated increases in costs or expenses; and risks associated with international operations. Information on these and additional risks and uncertainties and other information affecting Fluidigm's business and operating results is contained in its Annual Report on Form 10-K for the year ended December 31, 2019, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law.About Fluidigm Fluidigm (Nasdaq:FLDM) is an industry-leading biotechnology tools provider with a vision to improve life through comprehensive health insight. We focus on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit fluidigm.com. Fluidigm, the Fluidigm logo, Advanta, CyTOF, Direct, Hyperion, Imaging Mass Cytometry, Immune Profiling Assay, and Maxpar are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.Available Information We use our website (fluidigm.com), investor site (investors.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (facebook.com/Fluidigm), and LinkedIn page (linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.Contact:Investors: Agnes Lee Vice President, Investor Relations Fluidigm Corporation 650 416 7423 agnes.lee@fluidigm.comMedia: Mark Spearman Senior Director, Corporate Communications 650 243 6621 mark.spearman@fluidigm.com FLUIDIGM CORPORATION       CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In thousands, except per share amounts)       (Unaudited)                     Three Months Ended June 30, Six Months Ended June 30,    2020 2019 2020 2019 Revenue:            Product revenue   $17,405  $23,235  $36,386  $48,062    Service revenue  5,140  4,961  10,326  10,245  Product and service revenue  22,545  28,196  46,712  58,307    Other revenue  3,513  —  6,963  —  Total revenue  26,058  28,196  53,675  58,307  Costs and expenses:            Cost of product revenue  9,483  11,100  19,123  22,489    Cost of service revenue  1,237  1,733  2,762  3,465  Cost of product and service revenue  10,720  12,833   21,885   25,954    Research and development  8,448  7,865  17,147  16,237    Selling, general and administrative  20,616  22,134  43,311  44,958  Total costs and expenses  39,784  42,832  82,343  87,149  Loss from operations  (13,726) (14,636) (28,668) (28,842) Interest expense  (897) (491) (1,797) (3,192) Loss on extinguishment of debt  —  —  —  (9,000) Other income (expense), net  463  231  (355) 715  Loss before income taxes  (14,160) (14,896) (30,820) (40,319) Income tax benefit  1,145  1,143  1,825  1,101  Net loss  $(13,015) $(13,753) $(28,995) $(39,218) Net loss per share, basic and diluted  $(0.18) $(0.20) $(0.41) $(0.61) Shares used in computing net loss per share, basic and diluted  70,916  69,158  70,691  63,923                 FLUIDIGM CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) (Unaudited)             June 30, 2020 December 31, 2019 (1) ASSETS     Current assets:     Cash and cash equivalents (Note 2) $42,965  $21,661  Short-term investments (Note 2) 2,431  36,978  Accounts receivable, net 9,983  18,981  Inventories 18,900  13,884  Prepaid expenses and other current assets (Note 2) 4,171  4,592  Total current assets 78,450  96,096  Property and equipment, net 7,865  8,056  Operating lease right-of-use assets, net 39,027  4,860  Other non-current assets (Note 2) 5,034  5,492  Developed technology, net 45,644  46,200  Goodwill 106,328  104,108  Total assets $282,348  $264,812        LIABILITIES AND STOCKHOLDERS' EQUITY     Current liabilities:     Accounts payable $9,384  $6,510  Accrued compensation and related benefits 6,757  5,160  Operating lease liabilities, current 2,170  1,833  Other accrued liabilities 5,758  7,515  Deferred revenue, current portion 14,279  11,803  Total current liabilities 38,348  32,821  Convertible notes, net 54,013  53,821  Deferred tax liability, net 9,655  11,494  Operating lease liabilities, non-current 39,139  4,323  Deferred revenue, non-current 7,936  8,168  Other non-current liabilities 538  573  Total liabilities 149,629  111,200  Total stockholders' equity 132,719  153,612  Total liabilities and stockholders' equity $282,348  $264,812        Notes:     (1) Derived from audited consolidated financial statements     (2) Cash and cash equivalents, available for sale securities and restricted cash consist of:     Cash and cash equivalents $42,965  $21,661  Short-term investments 2,431  36,978  Restricted cash (included in prepaid and other current assets, and other non-current assets) 1,075  2,075  Total cash and cash equivalents, available for sale securities and restricted cash $46,471  $60,714        FLUIDIGM CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands) (Unaudited)         Six Months Ended June 30,   2020 2019 Operating activities     Net loss $(28,995) $(39,218) Depreciation and amortization 2,016  2,351  Stock-based compensation expense 6,000  5,263  Amortization of developed technology 5,936  5,600  Amortization of debt discounts, premium and issuance costs 275  2,037  Loss on extinguishment of debt —  9,000  Loss on disposal of property and equipment 148  29  Other non-cash items 1,773  467  Changes in assets and liabilities, net 5,762  (10,672) Net cash used in operating activities (7,085) (25,143)       Investing activities     Acquisition, net of cash acquired (5,154) —  Purchases of investments —  (44,614) Proceeds from sales and maturities of investments 34,411  —  Purchases of property and equipment (1,671) (685) Net cash provided by (used in) investing activities 27,586  (45,299)       Financing activities     Payment of debt issuance costs (375) (15) Proceeds from employee equity programs, net 383  1,202  Net cash provided by financing activities 8  1,187        Effect of foreign exchange rate fluctuations on cash and cash equivalents (205) (25) Net increase (decrease) in cash, cash equivalents and restricted cash 20,304  (69,280) Cash, cash equivalents and restricted cash at beginning of period 23,736  95,401  Cash, cash equivalents and restricted cash at end of period $44,040  $26,121        Cash and cash equivalents, restricted cash and available for sale securities consist of:     Cash and cash equivalents $42,965  $24,046  Short-term investments 2,431  44,815  Restricted cash (included in prepaid and other current assets, and other non-current assets) 1,075  2,075  Total cash and cash equivalents, available for sale securities and restricted cash $46,471  $70,936        FLUIDIGM CORPORATION         RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION     (In thousands, except per share amounts)         (Unaudited)                             ITEMIZED RECONCILIATION BETWEEN GAAP AND NON-GAAP NET LOSS             Three Months Ended June 30, Six Months Ended June 30,   2020 2019 2020 2019           Net loss (GAAP) $(13,015) $(13,753) $(28,995) $(39,218) Stock-based compensation expense 3,634  2,992  6,000  5,263  Amortization of developed technology (a) 2,968  2,800  5,936  5,600  Depreciation and amortization 924  1,160  2,016  2,351  Interest expense (b) 897  491  1,797  3,192  Loss on disposal of property and equipment 148  (41) 148  29  Loss on extinguishment of debt —  —  —  9,000  Benefit from acquisition related income taxes (c) (742) (742) (1,484) (1,484) Net loss (Non-GAAP) $(5,186) $(7,093) $(14,582) $(15,267) Shares used in net loss per share calculation -         basic and diluted (GAAP and Non-GAAP) 70,916  69,158  70,691  63,923            Net loss per share - basic and diluted (GAAP) $(0.18) $(0.20) $(0.41) $(0.61) Net loss per share - basic and diluted (Non-GAAP) $(0.07) $(0.10) $(0.21) $(0.24)           ITEMIZED RECONCILIATION BETWEEN GAAP AND NON-GAAP PRODUCT AND SERVICE MARGIN             Three Months Ended June 30, Six Months Ended June 30,   2020 2019 2020 2019 Product and service gross profit (GAAP) $11,825  $15,363  $24,827  $32,353  Amortization of developed technology (a) 2,800  2,800  5,600  5,600  Depreciation and amortization (d) 403  444  796  897  Stock-based compensation expense (d) 108  108  179  235  Product and service gross profit (Non-GAAP) $15,136  $18,715  $31,402  $39,085            Product and service margin percentage (GAAP) 52.5% 54.5% 53.1% 55.5% Product and service margin percentage (Non-GAAP) 67.1% 66.4% 67.2% 67.0%           ITEMIZED RECONCILIATION BETWEEN GAAP AND NON-GAAP OPERATING EXPENSES             Three Months Ended June 30, Six Months Ended June 30,   2020 2019 2020 2019 Operating expenses (GAAP) $29,064  $29,999  $60,458  $61,195  Stock-based compensation expense (e) (3,526) (2,884) (5,821) (5,028) Depreciation and amortization (e) (689) (716) (1,556) (1,454) Loss on disposal of property and equipment (e) (148) 41  (148) (29) Operating expenses (Non-GAAP) $24,701  $26,440  $52,933  $54,684                      ITEMIZED RECONCILIATION BETWEEN GAAP AND NON-GAAP LOSS FROM OPERATIONS               Three Months Ended June 30, Six Months Ended June 30,   2020 2019 2020 2019 Loss from operations (GAAP) $(13,726) $(14,636) $(28,668) $(28,842) Stock-based compensation expense 3,634  2,992  6,000  5,263  Amortization of developed technology (a) 2,968  2,800  5,936  5,600  Depreciation and amortization (e) 924  1,160  2,016  2,351  Loss on disposal of property and equipment (e) 148  (41) 148  29  Loss from operations (Non-GAAP) $(6,052) $(7,725) $(14,568) $(15,599)                     (a) represents amortization of developed technology in connection with the DVS acquisitions (b) represents interest expense, primarily on convertible debt         (c) represents the tax impact on the purchase of intangible assets in connection with the DVS acquisition (d) represents expense associated with cost of product revenue       (e) represents expense associated with research and development, selling, general and administrative activities

  • GlobeNewswire

    Fluidigm and De Novo Software to Offer Mass Cytometry Customers a Streamlined Solution for Data Analysis

    License for De Novo Software’s FCS Express 7 Flow to be Provided to Customers Purchasing Fluidigm Helios and Hyperion Imaging SystemsSOUTH SAN FRANCISCO, Calif., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced a distribution agreement with De Novo Software™ to provide customers with access to a data analysis solution for the high-parameter data files generated by mass cytometry using De Novo’s FCS Express™ 7 Flow software. Under the distribution agreement, new purchases of the Fluidigm® Helios™ mass cytometer and Hyperion™ Imaging System will include a one-year license for FCS Express 7 Flow for suspension data analysis. FCS Express enables rapid generation of analysis reports, manual or semi-automated high-dimensional analysis tools and custom report templates. De Novo Software has been a leading provider of cytometry analysis tools since 1998 and provides data analysis solutions for flow and mass cytometry and for Imaging Mass Cytometry™. FCS Express Flow, De Novo Software’s flagship product, is a popular cytometry analysis solution widely used by clinical, academic and pharmaceutical institutions. FCS Express Flow provides the flexibility to design custom analysis templates, with streamlined outputs into Microsoft® Office applications, while maintaining high-resolution graphics and reports.“There are more than 1,000 significant publications based on mass cytometry, a technology that provides researchers with extraordinary capabilities in interrogating the tissue microenvironment to explore important questions in developmental biology, disease progression and response to therapy,” said Chris Linthwaite, Fluidigm President and CEO. “In order to fully realize the value of these rich datasets, novel analysis methods are essential. We are pleased to offer our customers access to the considerable capabilities provided by De Novo’s software solutions.”FCS Express combines analysis capabilities, statistical applications and high-dimensional data reduction software in a single product.  “Fluidigm mass cytometry technology is the perfect partner for FCS Express,” said David Novo, President of De Novo Software. “Fluidigm continues to push the boundaries in high-parameter cytometry data, and FCS Express has all the high-dimensional data visualization and analysis tools required to handle such data without the need for researchers to become biostatisticians or  software coders. We are pleased to collaborate with Fluidigm to provide researchers with new and more powerful insights.”About Fluidigm Fluidigm (Nasdaq:FLDM) is an industry-leading biotechnology tools provider with a vision to improve life through comprehensive health insight. We focus on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all. For more information, visit fluidigm.com.Fluidigm, the Fluidigm logo, CyTOF, Helios, Hyperion, and Imaging Mass Cytometry are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are the sole property of their respective owners. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.About De Novo Software De Novo Software is a leading provider of flow and image cytometry data analysis. Its primary product, FCS Express, is used by over 3,000 laboratories worldwide for research purposes, and many clinical laboratories for high-throughput clinical analysis. As the first third-party flow analysis software listed with the FDA for in-vitro diagnostic use, and with a full suite of 21 CFR Part 11 compliance features, FCS Express is the analysis tool of choice for the clinical laboratory. In addition, De Novo Software has extensive experience creating custom data analysis solutions and integrating with large scale LIS and HIS systems. For more information, please visit www.denovosoftware.com/partnership-fluidigm.Forward-Looking Statements for Fluidigm This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, expected features and benefits of products and a software distribution arrangement. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to the potential adverse effects of the coronavirus pandemic on our business and operating results during 2020; challenges inherent in developing, manufacturing, launching, marketing, and selling new products; uncertainties in contractual relationships; risks relating to company research and development, sales, marketing, and distribution plans and capabilities; reductions in research and development spending or changes in budget priorities by customers; interruptions or delays in the supply of components or materials for, or manufacturing of, Fluidigm products; seasonal variations in customer operations; potential product performance and quality issues; intellectual property risks; and competition. Information on these and additional risks and uncertainties and other information affecting Fluidigm business and operating results is contained in Fluidigm’s Annual Report on Form 10-K for the year ended December 31, 2019, and in its other filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law.Available Information We use our website (fluidigm.com), investor site (investors.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (facebook.com/Fluidigm), and LinkedIn page (linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.Contacts: Media: Mark Spearman Senior Director, Corporate Communications 650 243 6621 mark.spearman@fluidigm.comInvestors: Agnes Lee Vice President, Investor Relations 650 416 7423 agnes.lee@fluidigm.com